3,4-dichloro-N-[(4-sulphamoylphenyl)carbamothioyl]benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,4-dichloro-N-[(4-sulphamoylphenyl)carbamothioyl]benzamide
• 英文别名: 1-(3,4-Dichlorobenzoyl)-3-(4-sulfamoyl)phenyl-2-thiourea；3,4-dichloro-N-[(4-sulfamoylphenyl)carbamothioyl]benzamide
• 化学式: C₁₄H₁₁Cl₂N₃O₃S₂
• 分子量: 404.298
• InChiKey: MMZABTLXRTYXIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  142
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3,4-二氯苯甲酸 在 氯化亚砜 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 生成 3,4-dichloro-N-[(4-sulphamoylphenyl)carbamothioyl]benzamide
  参考文献：
  名称：

  一些针对碳酸酐酶的新型苯甲酰硫脲基苯基衍生物的设计与合成

  摘要：

  摘要 本研究旨在开发有效的碳酸酐酶抑制剂 (CAI)。目标化合物的设计基于对脲基碳酸酐酶抑制剂 SLC-0111 的结构的修饰。制备了六个系列的具有不同锌结合基团的取代苯甲酰硫脲基核；常规的氨基磺酸基团4a-d和12a-c，其生物等排羧酸基团5a-d和13a-c或羧酸乙酯基团6a-d和14a-c作为潜在的前药。评估了所有化合物对一组四种生理相关的人 CA 同种型 hCA I 和 hCA II、hCA IX 和 hCA XII 的碳酸酐酶 (CA) 抑制活性。化合物4a、4b、4c、4d、5d、12a和12c显示出对hCA I的显着抑制活性，这将突出这些化合物作为治疗青光眼的有希望的候选药物。

  DOI：

  10.1080/14756366.2022.2126463

文献信息

• Two-component initiator system (amine-free) with very good storage stability and particular suitability for acid systems
  申请人：Utterodt Andreas

  公开号：US20070040151A1

  公开（公告）日：2007-02-22

  A two-component initiator system having accelerators for curing polymerizable materials comprising the following components: (a) a hydroperoxide compound containing one or more hydroperoxide groups that are bound to a tertiary carbon; (b) a thiourea derivative; and (c) as accelerator, a copper compound which is soluble in the preparation is preferably free of amine and is particularly suited for polymerizable dental compositions.
• Pharmaceutical Compositions For and Methods of Inhibiting Hcv
  申请人：Huang Mingjun

  公开号：US20080207760A1

  公开（公告）日：2008-08-28

  The present invention relates generally to replicase complex defect inducers and pharmaceutical compositions containing such inducers. Methods of developing mutants that are resistant to replicase complex defect inducers are also provided. Further included are mutants that can be used in screening for replicase complex defect inducers. Methods of screening test compounds for the ability to induce the formation of replicase complex defects are also described. Also included are methods of inhibition of HCV replication by replicase complex defect inducers.
• Design and synthesis of some new benzoylthioureido phenyl derivatives targeting carbonic anhydrase enzymes
  作者：Mazin A. A. Najm、Walaa R. Mahmoud、Azza T. Taher、Safinaz E-S. Abbas、Fadi M. Awadallah、Heba Abdelrasheed Allam、Daniela Vullo、Claudiu T. Supuran

  DOI：10.1080/14756366.2022.2126463

  日期：2022.12.31

  Abstract The present study aimed to develop potent carbonic anhydrase inhibitors (CAIs). The design of the target compounds was based on modifying the structure of the ureido-based carbonic anhydrase inhibitor SLC-0111. Six series of a substituted benzoylthioureido core were prepared featuring different zinc-binding groups; the conventional sulphamoyl group 4a–d and 12a–c, its bioisosteric carboxylic

  摘要 本研究旨在开发有效的碳酸酐酶抑制剂 (CAI)。目标化合物的设计基于对脲基碳酸酐酶抑制剂 SLC-0111 的结构的修饰。制备了六个系列的具有不同锌结合基团的取代苯甲酰硫脲基核；常规的氨基磺酸基团4a-d和12a-c，其生物等排羧酸基团5a-d和13a-c或羧酸乙酯基团6a-d和14a-c作为潜在的前药。评估了所有化合物对一组四种生理相关的人 CA 同种型 hCA I 和 hCA II、hCA IX 和 hCA XII 的碳酸酐酶 (CA) 抑制活性。化合物4a、4b、4c、4d、5d、12a和12c显示出对hCA I的显着抑制活性，这将突出这些化合物作为治疗青光眼的有希望的候选药物。